Turbin.ai is a Budapest-based biotechnology company founded in 2015 by Daniel Veres, Kristóf Zsolt Szalay, and Szabolcs Nagy. The company specializes in integrating artificial intelligence (AI) with biomedical research to enhance drug discovery processes. By leveraging AI-driven simulations, Turbin.ai aims to predict cellular responses to various treatments, thereby accelerating the development of effective therapies.
Key Strategic Focus
Turbin.ai's strategic focus centers on utilizing AI to model and simulate cellular behavior, enabling the identification of potential drug candidates more efficiently. The company's proprietary platform combines machine learning algorithms with extensive biological data to predict how cells react to different compounds. This approach targets complex diseases, aiming to streamline the drug discovery pipeline and reduce the time and cost associated with bringing new therapies to market.
Financials and Funding
Since its inception, Turbin.ai has secured a total of $31.1 million across three funding rounds:
- November 2019 (Seed Round): Raised $3.5 million.
- January 2021 (Series A): Secured $7 million.
- November 2022 (Series A): Obtained $20.6 million.
These funds are intended to enhance the company's AI platform, expand research capabilities, and support the development of new drug candidates.
Technological Platform and Innovation
Turbin.ai's innovation lies in its AI-driven simulation platform, which models cellular responses to various treatments. This technology integrates machine learning with biological data to predict the efficacy and safety of potential drug compounds. By simulating complex biological processes, the platform aims to identify promising drug candidates and optimize therapeutic strategies, setting Turbin.ai apart in the biotech industry.
Leadership Team
- Daniel Veres: Co-founder and Chief Scientific Officer.
- Kristóf Zsolt Szalay: Co-founder and Chief Technology Officer.
- Szabolcs Nagy: Co-founder and Chief Executive Officer.
The leadership team brings a wealth of experience in biotechnology, AI, and business development, driving Turbin.ai's mission to revolutionize drug discovery through technological innovation.
Competitor Profile
Turbin.ai operates in the competitive landscape of AI-driven drug discovery, with notable competitors including:
- Xellar, Inc.: Combines AI and large-scale wet-lab experiments to tackle challenges in modern drug discovery.
- Seismic Therapeutic: Integrates machine learning across the biologics discovery process to accelerate immunology drug development.
- Genesis Therapeutics: Unifies AI and biotechnology to optimize the development of new medicines.
These companies, like Turbin.ai, leverage AI and machine learning to enhance various aspects of the drug discovery and development process.
Strategic Collaborations and Partnerships
In July 2025, Turbin.ai partnered with GQR, a global leader in specialized talent acquisition, to launch the GQR x Turbin Workday Talent Marketplace. This platform provides Workday customers and partners with direct access to elite, pre-vetted consultants, enhancing the efficiency of talent acquisition within the Workday ecosystem. The marketplace offers real-time visibility into consultant availability, faster hiring cycles, and AI-supported matching, combining Turbin.ai's advanced AI capabilities with GQR's expertise in sourcing elite talent.
Operational Insights
Turbin.ai's AI-driven simulation platform offers a distinct competitive advantage by enabling rapid and accurate predictions of cellular responses to treatments. This capability allows for the identification of promising drug candidates and optimization of therapeutic strategies, positioning the company as a leader in AI-driven drug discovery.
Strategic Opportunities and Future Directions
Looking ahead, Turbin.ai aims to expand its AI platform's capabilities, explore new therapeutic areas, and establish additional strategic partnerships to enhance its drug discovery processes. By leveraging its technological strengths and collaborative initiatives, the company is well-positioned to make significant contributions to the biotechnology industry.
Contact Information
- Website
